Abstract
DNA vaccines promote immune system activation in small animals and exhibit certain advantages when compared to conventional recombinant protein vaccines. However in clinical trials DNA vaccines are less effective in inducing potent immune responses due to the low delivery efficiency and expression of antigens. Currently, various delivery devices such as gene-guns, bioinjectors and electroporation systems are being used in order to increase the potency of DNA vaccines. However, the optimal delivery parameters are required and must be carefully set to obtain the highest levels of gene expression and strong immune responses in humans. The focus of this study was to optimize electroporation settings (voltage, pulse length, pulse intervals, and number of pulses), as well as the route of administration (intradermal vs. intramuscular) and dosage of the DNA epitope vaccine, AV-1959D, delivered by the BTX AgilePulseTM system. As a result, we have chosen the optimal settings for electroporation delivery using different routes of immunization with this vaccine, generating (i) robust antibody production to the B cell epitope (a small peptide, derived from β-amyloid), and (ii) strong cellular immune responses to Th epitopes (a small synthetic peptide and eleven peptides from various pathogens) incorporated into DNA vaccine platform.
Keywords: AV-1959D vaccine, electroporation device, immune responses, intradermal delivery, intramuscular delivery, optimization of BTX AgilePulseTM system, plasmid immunizations.
Current Gene Therapy
Title:BTX AgilePulseTM System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine
Volume: 14 Issue: 3
Author(s): Hayk Davtyan, Armine Hovakimyan, Karen Zagorski, Arpine Davtyan, Irina Petrushina, David Agdashian, Vidya Murthy, David H. Cribbs, Michael G. Agadjanyan and Anahit Ghochikyan
Affiliation:
Keywords: AV-1959D vaccine, electroporation device, immune responses, intradermal delivery, intramuscular delivery, optimization of BTX AgilePulseTM system, plasmid immunizations.
Abstract: DNA vaccines promote immune system activation in small animals and exhibit certain advantages when compared to conventional recombinant protein vaccines. However in clinical trials DNA vaccines are less effective in inducing potent immune responses due to the low delivery efficiency and expression of antigens. Currently, various delivery devices such as gene-guns, bioinjectors and electroporation systems are being used in order to increase the potency of DNA vaccines. However, the optimal delivery parameters are required and must be carefully set to obtain the highest levels of gene expression and strong immune responses in humans. The focus of this study was to optimize electroporation settings (voltage, pulse length, pulse intervals, and number of pulses), as well as the route of administration (intradermal vs. intramuscular) and dosage of the DNA epitope vaccine, AV-1959D, delivered by the BTX AgilePulseTM system. As a result, we have chosen the optimal settings for electroporation delivery using different routes of immunization with this vaccine, generating (i) robust antibody production to the B cell epitope (a small peptide, derived from β-amyloid), and (ii) strong cellular immune responses to Th epitopes (a small synthetic peptide and eleven peptides from various pathogens) incorporated into DNA vaccine platform.
Export Options
About this article
Cite this article as:
Davtyan Hayk, Hovakimyan Armine, Zagorski Karen, Davtyan Arpine, Petrushina Irina, Agdashian David, Murthy Vidya, Cribbs H. David, Agadjanyan G. Michael and Ghochikyan Anahit, BTX AgilePulseTM System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine, Current Gene Therapy 2014; 14 (3) . https://dx.doi.org/10.2174/1566523214666140522121427
DOI https://dx.doi.org/10.2174/1566523214666140522121427 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Non-Small Cell Lung Cancer: From Cytotoxic Systemic Chemotherapy to Molecularly Targeted Therapy
Current Medicinal Chemistry - Anti-Cancer Agents KRAS: A Promising Therapeutic Target for Cancer Treatment
Current Topics in Medicinal Chemistry Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Nanoceria: Synthesis and Biomedical Applications
Current Nanoscience Canine Nutritional Model: Influence of Age, Diet, and Genetics on Health and Well-Being
Current Nutrition & Food Science Advances in Early Detection of Colorectal Cancer: A Focus on Non-invasive Biomarkers
Current Drug Targets The ModifiedGlasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature
Reviews on Recent Clinical Trials Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery iLoc-Gpos: A Multi-Layer Classifier for Predicting the Subcellular Localization of Singleplex and Multiplex Gram-Positive Bacterial Proteins
Protein & Peptide Letters Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Prostate Cancer Molecular Background: The IGF-1Ec Story
Clinical Cancer Drugs Identifying Biomarkers of Lung Cancer in the Post-Genomic Era
Current Pharmacogenomics Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention
Current Pharmaceutical Biotechnology Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives
Current Drug Therapy Editorial (Thematic Issue: Polymers in Drug Delivery)
Current Pharmaceutical Design